Switch theme
Sign up to access all valuation multiples
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.
1999
n/a
LTM Revenue $5.2M
LTM EBITDA -$7.8M
$45.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Actinogen Medical has a last 12-month revenue of $5.2M and a last 12-month EBITDA of -$7.8M.
In the most recent fiscal year, Actinogen Medical achieved revenue of n/a and an EBITDA of -$8.0M.
Actinogen Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Actinogen Medical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$6.5M | -$8.0M | XXX | XXX | XXX |
| EBITDA Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Profit | -$6.0M | -$6.8M | XXX | XXX | XXX |
| Net Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, Actinogen Medical's stock price is AUD 0 (or $0).
Actinogen Medical has current market cap of AUD 94.0M (or $59.4M), and EV of AUD 71.4M (or $45.2M).
See Actinogen Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $45.2M | $59.4M | XXX | XXX | XXX | XXX | $-0.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, Actinogen Medical has market cap of $59.4M and EV of $45.2M.
Actinogen Medical's trades at 8.6x LTM EV/Revenue multiple, and -5.8x LTM EBITDA.
Analysts estimate Actinogen Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Actinogen Medical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $45.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -5.8x | XXX | XXX | XXX |
| P/E | -7.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -5.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpActinogen Medical's NTM/LTM revenue growth is 25%
Actinogen Medical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Actinogen Medical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Actinogen Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Actinogen Medical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Actinogen Medical acquired XXX companies to date.
Last acquisition by Actinogen Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Actinogen Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Actinogen Medical founded? | Actinogen Medical was founded in 1999. |
| Where is Actinogen Medical headquartered? | Actinogen Medical is headquartered in Australia. |
| Is Actinogen Medical publicy listed? | Yes, Actinogen Medical is a public company listed on ASX. |
| What is the stock symbol of Actinogen Medical? | Actinogen Medical trades under ACW ticker. |
| When did Actinogen Medical go public? | Actinogen Medical went public in 2007. |
| Who are competitors of Actinogen Medical? | Similar companies to Actinogen Medical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Actinogen Medical? | Actinogen Medical's current market cap is $59.4M |
| What is the current revenue of Actinogen Medical? | Actinogen Medical's last 12-month revenue is $5.2M. |
| What is the current EBITDA of Actinogen Medical? | Actinogen Medical's last 12-month EBITDA is -$7.8M. |
| What is the current EV/Revenue multiple of Actinogen Medical? | Current revenue multiple of Actinogen Medical is 8.6x. |
| What is the current EV/EBITDA multiple of Actinogen Medical? | Current EBITDA multiple of Actinogen Medical is -5.8x. |
| Is Actinogen Medical profitable? | Yes, Actinogen Medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
